446 related articles for article (PubMed ID: 32492514)
21. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Quintanal-Villalonga A; Molina-Pinelo S; Yagüe P; Marrugal Á; Ojeda-Márquez L; Suarez R; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
Lung Cancer; 2019 May; 131():112-121. PubMed ID: 31027687
[TBL] [Abstract][Full Text] [Related]
22. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.
Wachtel M; Rakic J; Okoniewski M; Bode P; Niggli F; Schäfer BW
Int J Cancer; 2014 Oct; 135(7):1543-52. PubMed ID: 24550147
[TBL] [Abstract][Full Text] [Related]
23. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
25. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
26. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
[TBL] [Abstract][Full Text] [Related]
28. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
[TBL] [Abstract][Full Text] [Related]
29. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.
Roidl A; Foo P; Wong W; Mann C; Bechtold S; Berger HJ; Streit S; Ruhe JE; Hart S; Ullrich A; Ho HK
Oncogene; 2010 Mar; 29(10):1543-52. PubMed ID: 19946327
[TBL] [Abstract][Full Text] [Related]
30. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
31. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
32. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
Yamauchi M; Ono A; Ishikawa A; Kodama K; Uchikawa S; Hatooka H; Zhang P; Teraoka Y; Morio K; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Hayes CN; Fujita M; Nakagawa H; Yasui W; Aikata H; Chayama K
Clin Transl Gastroenterol; 2020 May; 11(5):e00179. PubMed ID: 32677805
[TBL] [Abstract][Full Text] [Related]
33. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
34. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S; Thennavan A; East MP; Parker JS; Cejalvo JM; Garay JP; Hollern DP; He X; Mott KR; Galván P; Fan C; Selitsky SR; Coffey AR; Marron D; Brasó-Maristany F; Burgués O; Albanell J; Rojo F; Lluch A; de Dueñas EM; Rosen JM; Johnson GL; Carey LA; Prat A; Perou CM
J Clin Invest; 2020 Sep; 130(9):4871-4887. PubMed ID: 32573490
[TBL] [Abstract][Full Text] [Related]
35. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
36. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
37. FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.
Turunen SP; von Nandelstadh P; Öhman T; Gucciardo E; Seashore-Ludlow B; Martins B; Rantanen V; Li H; Höpfner K; Östling P; Varjosalo M; Lehti K
Cell Death Differ; 2019 Dec; 26(12):2577-2593. PubMed ID: 30903103
[TBL] [Abstract][Full Text] [Related]
38. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets.
Tenhagen M; van Diest PJ; Ivanova IA; van der Wall E; van der Groep P
Endocr Relat Cancer; 2012 Aug; 19(4):R115-29. PubMed ID: 22508544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
